Cite
Retinoid X receptor agonists attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes through LKB1-dependent anti-fibrosis effects.
MLA
Dajun Chai, et al. “Retinoid X Receptor Agonists Attenuates Cardiomyopathy in Streptozotocin-Induced Type 1 Diabetes through LKB1-Dependent Anti-Fibrosis Effects.” Clinical Science, vol. 134, no. 6, Mar. 2020, pp. 609–28. EBSCOhost, https://doi.org/10.1042/CS20190985.
APA
Dajun Chai, Xiaoyan Lin, Qiaowen Zheng, Changsheng Xu, Hong Xie, Qinyun Ruan, Jinxiu Lin, Jie Liu, & Jinzhang Zeng. (2020). Retinoid X receptor agonists attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes through LKB1-dependent anti-fibrosis effects. Clinical Science, 134(6), 609–628. https://doi.org/10.1042/CS20190985
Chicago
Dajun Chai, Xiaoyan Lin, Qiaowen Zheng, Changsheng Xu, Hong Xie, Qinyun Ruan, Jinxiu Lin, Jie Liu, and Jinzhang Zeng. 2020. “Retinoid X Receptor Agonists Attenuates Cardiomyopathy in Streptozotocin-Induced Type 1 Diabetes through LKB1-Dependent Anti-Fibrosis Effects.” Clinical Science 134 (6): 609–28. doi:10.1042/CS20190985.